A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: Implications for clinical practice

Oncologist

Volumn 19, Issue 5, 2014, Pages 453-458

  Vasan, Neil ^a   Yelensky, Roman ^b   Wang, Kai ^b   Moulder, Stacy ^c   Dzimitrowicz, Hannah ^a   Avritscher, Rony ^c   Wang, Baliang ^c   Wu, Yun ^c   Cronin, Maureen T ^b   Palmer, Gary ^b   Fraser Symmans, W ^c   Miller, Vincent A ^b   Stephens, Philip ^b   Pusztai, Lajos ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOUNDATION MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Molecularly targeted therapy; Next generation sequencing; Precision medicine; Predictive markers

Indexed keywords

BIOLOGICAL MARKER; CRIZOTINIB; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROFIBROMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B INHIBITOR; PROTEIN MCL 1; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST METASTASIS; CHROMOSOME REARRANGEMENT; COPY NUMBER VARIATION; DNA EXTRACTION; DNA SEQUENCE; DRUG TARGETING; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE FUSION; GENE MUTATION; GENOME ANALYSIS; HER2 GENE; HUMAN; HUMAN TISSUE; INDEL MUTATION; MAJOR CLINICAL STUDY; MCL1 GENE; NF1 GENE; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE K RAS; ONCOGENE MYC; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; TUMOR SUPPRESSOR GENE; BREAST TUMOR; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BREAST NEOPLASMS; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 84900031607     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0377     Document Type: Article

References (29)

1. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357: 39-51.
2. Capdeville R, Buchdunger E, Zimmermann J et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
3. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancertogefitinib. N Engl J Med 2004;350:2129-2139.
4. Gandhi L, Janne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: A new targeted therapy for a new target. Clin Cancer Res 2012;18:3737-3742.
5. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
7. Kan Z, Jaiswal BS, Stinson J et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010;466:869-873.
8. Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-697.
9. Kim KB, Cabanillas ME, Lazar AJ et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF (V600E) mutation. Thyroid 2013;23:1277-1283.
10. Stephens PJ, Tarpey PS, Davies H et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-404.
11. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-351.
12. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-813.
13. MacConaill LE, Campbell CD, Kehoe SM et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009;4:e7887.
14. Santarpia L, Qi Y, Stemke-Hale K et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012;134:333-343.
15. Jurinke C, Oeth P, van den Boom D. MALDI-TOF mass spectrometry: A versatile tool for high-performance DNA analysis. Mol Biotechnol 2004; 26:147-164.
16. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
17. Moulder S. Personalized Treatment Selection for Metastatic Breast Cancer (NCT00780676). Available at http://clinicaltrials.gov/ct2/show/NCT00780676?term = nct00780676&rank=1. Accessed March 17, 2014.
18. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNAsequencing. Nat Biotechnol 2013;31:1023-1031.
19. Greulich H, Kaplan B, Mertins P et al. Functional analysis of receptortyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 2012;109:14476-14481.
20. Bose R, Kavuri SM, Searleman AC et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3: 224-237.
21. Willmore C, Holden JA, Zhou L et al. Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Pathol 2004;122:206-216.
22. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008;21:492-493.
23. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17:2081-2086.
24. Bleeker FE, Felicioni L, Buttitta F et al. AKT1 (E17K) in human solid tumours. Oncogene 2008;27: 5648-5650.
25. Conti RM, Bernstein AC, Villaflor VM et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 2013;31:1134-1139.
26. Dienstmann R, Serpico D, Rodon J et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol CancerTher 2012;11:2062-2071.
27. Pusztai L. Breast Cancer Molecular Analysis Protocol (MAP-IT) (NCT01855503). Available at http://clinicaltrials.gov/ct2/show/NCT01855503?term=NCT01855503&rank=1. Accessed March 17, 2014.
28. Willyard C. 'Basket studies' will hold intricate data for cancer drug approvals. Nat Med 2013;19: 655.
29. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 2004;291:2720-2726.